PIN4

Summary

PIN4 (peptidylprolyl cis/trans isomerase, NIMA-interacting 4, HGNC:8992) is a protein-coding gene on chromosome Xq13.1, encoding Peptidyl-prolyl cis-trans isomerase NIMA-interacting 4 (Q9Y237). Isoform 1 is involved as a ribosomal RNA processing factor in ribosome biogenesis.

This gene encodes a member of the parvulin subfamily of the peptidyl-prolyl cis/trans isomerase protein family. The encoded protein catalyzes the isomerization of peptidylprolyl bonds, and may play a role in the cell cycle, chromatin remodeling, and/or ribosome biogenesis. The encoded protein may play an additional role in the mitochondria.

Source: NCBI Gene 5303 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 42 total
• Druggable target: yes
• MANE Select transcript: NM_006223

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8992
Approved symbol	PIN4
Name	peptidylprolyl cis/trans isomerase, NIMA-interacting 4
Location	Xq13.1
Locus type	gene with protein product
Status	Approved
Aliases	PAR14, PAR17, EPVH
Ensembl gene	ENSG00000102309
Ensembl biotype	protein_coding
OMIM	300252
Entrez	5303

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 8 protein_coding, 2 nonsense_mediated_decay

ENST00000218432, ENST00000373662, ENST00000373669, ENST00000423432, ENST00000439980, ENST00000446576, ENST00000496835, ENST00000652108, ENST00000664196, ENST00000913143

RefSeq mRNA: 2 — MANE Select: NM_006223 NM_001170747, NM_006223

CCDS: CCDS14417, CCDS55447

Canonical transcript exons

ENST00000373669 — 4 exons

Exon	Start	End
ENSE00000672615	72186461	72186534
ENSE00000672618	72196785	72196904
ENSE00001461195	72197368	72198340
ENSE00002064549	72181757	72181828

Expression profiles

Bgee: expression breadth ubiquitous, 290 present calls, max score 98.84.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.1235 / max 775.5929, expressed in 1737 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
196725	12.8166	1731
196724	0.3069	132

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tendon of biceps brachii	UBERON:0008188	98.84	gold quality
cervix squamous epithelium	UBERON:0006922	98.81	gold quality
tongue squamous epithelium	UBERON:0006919	98.03	gold quality
squamous epithelium	UBERON:0006914	97.97	gold quality
gingival epithelium	UBERON:0001949	97.91	gold quality
amniotic fluid	UBERON:0000173	97.85	gold quality
esophagus squamous epithelium	UBERON:0006920	97.83	gold quality
germinal epithelium of ovary	UBERON:0001304	97.66	gold quality
buccal mucosa cell	CL:0002336	97.62	gold quality
hair follicle	UBERON:0002073	97.37	gold quality
epithelial cell of pancreas	CL:0000083	97.22	gold quality
pancreatic ductal cell	CL:0002079	97.04	gold quality
palpebral conjunctiva	UBERON:0001812	96.91	gold quality
epithelium of esophagus	UBERON:0001976	96.66	gold quality
nephron tubule	UBERON:0001231	96.45	gold quality
parietal pleura	UBERON:0002400	96.19	gold quality
sperm	CL:0000019	96.16	gold quality
gingiva	UBERON:0001828	96.09	gold quality
pleura	UBERON:0000977	95.99	gold quality
epithelium of nasopharynx	UBERON:0001951	95.94	gold quality
medial globus pallidus	UBERON:0002477	95.91	gold quality
visceral pleura	UBERON:0002401	95.89	gold quality
male germ cell	CL:0000015	95.86	gold quality
cervix epithelium	UBERON:0004801	95.51	gold quality
Brodmann (1909) area 23	UBERON:0013554	95.23	gold quality
globus pallidus	UBERON:0001875	95.22	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	94.98	gold quality
biceps brachii	UBERON:0001507	94.67	gold quality
kidney epithelium	UBERON:0004819	94.54	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	94.47	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.25

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

35 targeting PIN4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-380-3P	99.89	70.18	1978
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-6757-3P	99.63	66.88	1089
HSA-MIR-4499	99.62	67.29	1470
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-3123	99.47	67.15	2693
HSA-MIR-766-5P	99.47	67.91	2225
HSA-MIR-6505-3P	99.34	67.39	1071
HSA-MIR-219A-1-3P	98.91	67.87	639
HSA-MIR-4680-3P	98.64	68.60	2093
HSA-MIR-4691-5P	98.41	66.77	1343
HSA-MIR-6792-3P	98.41	66.86	1359
HSA-MIR-6818-5P	97.50	67.10	1167
HSA-MIR-6831-3P	97.49	69.29	505
HSA-MIR-148B-5P	97.29	66.30	992
HSA-MIR-6874-3P	97.29	66.34	975
HSA-MIR-3192-5P	96.98	65.76	1926
HSA-MIR-6857-3P	96.70	65.43	915
HSA-MIR-5702	96.68	68.21	958

Literature-anchored findings (GeneRIF, showing 9)

• The N-terminal basic domain of human parvulin hPar14 is responsible for the entry to the nucleus and high-affinity DNA-binding. (PMID:12144781)
• subcellular localization and DNA binding properties of hPar14 are regulated by phosphorylation of the N-terminal domain (PMID:12860119)
• Identification of a longer Parvulin isoform (Par17) that has an extension at the 5’ end including a 75 bp extended open reading frame. (PMID:16522211)
• Data indicate the association of Par14 with insulin receptor substrate 1 (IRS-1) in human HepG2 cells overexpressing both as well as endogenously in the mouse liver. (PMID:23720771)
• Data indicate that Pin1 prolyl isomerase active site cysteine, Cys113, is highly susceptible to oxidation. (PMID:25595659)
• Par14 can be described as an endogenous non-histone chromatin protein, which binds DNA in vivo (PMID:25645591)
• Ca(2+)/Calmodulin binding to the N-terminal of Par17 causes steric hindrance of the Par17 active site, thus interfering with the Par17/tubulin interaction. (PMID:25940090)
• Numerous other proteins in addition to PIN1 are endowed with PPIase activity. These include other members of the parvulin family to which PIN1 belongs, such as PIN4, as well as several cyclophilins and FK506-binding proteins…This review will discuss studies providing evidence for multiple roles of PIN1 and other PPIases in glioblastoma and medulloblastoma, the most frequent adult and pediatric primary brain tumors. (PMID:30314361)
• Par14 interacts with the androgen receptor, augmenting both its transcriptional activity and prostate cancer proliferation. (PMID:36583514)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	pin4	ENSDARG00000004527
mus_musculus	Pin4	ENSMUSG00000079480
rattus_norvegicus	Pin4	ENSRNOG00000050051
drosophila_melanogaster	CG11858	FBGN0039305
caenorhabditis_elegans		WBGENE00012996

Paralogs (1): PIN1 (ENSG00000127445)

Protein

Protein identifiers

Peptidyl-prolyl cis-trans isomerase NIMA-interacting 4 — Q9Y237 (reviewed: Q9Y237)

Alternative names: Parvulin-14, Parvulin-17, Peptidyl-prolyl cis-trans isomerase Pin4, Peptidyl-prolyl cis/trans isomerase EPVH, Rotamase Pin4

All UniProt accessions (7): Q9Y237, A0A494C021, D6RFY5, H0Y4T6, H0Y610, H0Y8P6, J3KMW3

UniProt curated annotations — full annotation on UniProt →

Function. Isoform 1 is involved as a ribosomal RNA processing factor in ribosome biogenesis. Binds to tightly bent AT-rich stretches of double-stranded DNA. Isoform 2 binds to double-stranded DNA.

Subunit / interactions. Isoform 1 is found in pre-ribosomal ribonucleoprotein (pre-rRNP) complexes.

Subcellular location. Nucleus. Nucleolus. Cytoplasm. Cytoskeleton. Spindle. Cytoplasm Mitochondrion. Mitochondrion matrix.

Tissue specificity. Isoform 2 is much more stable than isoform 1 (at protein level). Ubiquitous. Isoform 1 and isoform 2 are expressed in kidney, liver, blood vessel, brain, mammary gland, skeletal muscle, small intestine and submandibularis. Isoform 1 transcripts are much more abundant than isoform 2 in each tissue analyzed.

Post-translational modifications. Phosphorylated. Isoform 1 phosphorylation occurs both in the nucleus and the cytoplasm. Isoform 1 phosphorylation at Ser-19 does not affect its PPIase activity but is required for nuclear localization, and the dephosphorylation is a prerequisite for the binding to DNA. The unphosphorylated isoform 1 associates with the pre-rRNP complexes in the nucleus. Isoform 2 is sumoylated with SUMO2 and SUMO3.

Domain organisation. The PPIase domain enhances mitochondrial targeting.

Miscellaneous. The first 25 amino acids are sufficient for mitochondrial targeting.

Similarity. Belongs to the PpiC/parvulin rotamase family. PIN4 subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9Y237-1	1	yes
Q9Y237-2	2
Q9Y237-3	3

RefSeq proteins (2): NP_001164218, NP_006214* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000297	PPIase_PpiC	Domain
IPR043323	PIN4	Family
IPR046357	PPIase_dom_sf	Homologous_superfamily

Pfam: PF13616

Catalyzed reactions (Rhea), 1 shown:

• [protein]-peptidylproline (omega=180) = [protein]-peptidylproline (omega=0) (RHEA:16237)

UniProt features (23 total): strand 5, helix 4, region of interest 3, mutagenesis site 2, sequence variant 2, splice variant 2, chain 1, domain 1, turn 1, compositionally biased region 1, modified residue 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
3UI4	X-RAY DIFFRACTION	0.8
3UI6	X-RAY DIFFRACTION	0.89
3UI5	X-RAY DIFFRACTION	1.4
1EQ3	SOLUTION NMR
1FJD	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y237-F1	80.28	0.33

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 19

Mutagenesis-validated functional residues (2):

Position	Phenotype
19	does not abolish nuclear localization and reduces dna-binding ability.
19	abolishes phosphorylation and strongly reduces nuclear localization.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 107 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_UP, GOBP_RIBOSOME_BIOGENESIS, MULLIGHAN_NPM1_SIGNATURE_3_UP, ONKEN_UVEAL_MELANOMA_UP, BLALOCK_ALZHEIMERS_DISEASE_UP, TIEN_INTESTINE_PROBIOTICS_24HR_UP, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP, GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS, GOCC_SPINDLE, GOCC_PRERIBOSOME, GOCC_MITOCHONDRIAL_MATRIX, GOCC_NUCLEOLUS, GOCC_RIBONUCLEOPROTEIN_COMPLEX, GOMF_CIS_TRANS_ISOMERASE_ACTIVITY, RHEIN_ALL_GLUCOCORTICOID_THERAPY_DN

GO Biological Process (1): rRNA processing (GO:0006364)

GO Molecular Function (7): DNA binding (GO:0003677), bent DNA binding (GO:0003681), double-stranded DNA binding (GO:0003690), RNA binding (GO:0003723), peptidyl-prolyl cis-trans isomerase activity (GO:0003755), protein binding (GO:0005515), isomerase activity (GO:0016853)

GO Cellular Component (10): nucleus (GO:0005634), nucleoplasm (GO:0005654), chromosome (GO:0005694), nucleolus (GO:0005730), cytoplasm (GO:0005737), mitochondrial matrix (GO:0005759), spindle (GO:0005819), preribosome (GO:0030684), mitochondrion (GO:0005739), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular membraneless organelle	4
nucleic acid binding	2
DNA binding	2
intracellular membrane-bounded organelle	2
nuclear lumen	2
cellular anatomical structure	2
RNA processing	1
rRNA metabolic process	1
ribosome biogenesis	1
cis-trans isomerase activity	1
catalytic activity, acting on a protein	1
binding	1
catalytic activity	1
intracellular anatomical structure	1
mitochondrion	1
intracellular organelle lumen	1
microtubule cytoskeleton	1
ribonucleoprotein complex	1
cytoplasm	1

Protein interactions and networks

STRING

2873 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PIN4	FKBP1A	P20071	803
PIN4	EPRS1	P07814	724
PIN4	NKTR	P30414	667
PIN4	PLK1	P53350	552
PIN4	NR1I2	O75469	542
PIN4	GLRX5	Q86SX6	530
PIN4	PPIG	Q13427	498
PIN4	CLK1	P49759	497
PIN4	AMACR	Q9UHK6	473
PIN4	F2R	P25116	472
PIN4	PIN1	Q13526	463
PIN4	NUCLEOLIN	P19338	459
PIN4	CLIC2	O15247	444
PIN4	RPS19	P39019	437
PIN4	POLR2A	P24928	431

IntAct

44 interactions, top by confidence:

A	B	Type	Score
FAM9B	PIN4	psi-mi:“MI:0915”(physical association)	0.670
PIN4	ZBTB9	psi-mi:“MI:0915”(physical association)	0.670
PIN4	CEP72	psi-mi:“MI:0915”(physical association)	0.670
PIN4	FAM9B	psi-mi:“MI:0915”(physical association)	0.670
CEP72	PIN4	psi-mi:“MI:0915”(physical association)	0.670
ERH	SNRPD3	psi-mi:“MI:0914”(association)	0.580
PIN4	MAGEA11	psi-mi:“MI:0915”(physical association)	0.560
PIN4	PNMA1	psi-mi:“MI:0915”(physical association)	0.560
FATE1	PIN4	psi-mi:“MI:0915”(physical association)	0.560
MAGEA11	PIN4	psi-mi:“MI:0915”(physical association)	0.560
PIN4	FATE1	psi-mi:“MI:0915”(physical association)	0.560
EGFR	PIN4	psi-mi:“MI:0915”(physical association)	0.550
PIN4	EGFR	psi-mi:“MI:0915”(physical association)	0.550
	GNAT3	psi-mi:“MI:0915”(physical association)	0.400
PIN4	CHST15	psi-mi:“MI:0915”(physical association)	0.400
PIN4	E7	psi-mi:“MI:0915”(physical association)	0.370
ERBB2	PIN4	psi-mi:“MI:0915”(physical association)	0.370
ERBB3	PIN4	psi-mi:“MI:0915”(physical association)	0.370
ERBB4	PIN4	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (86): PIN4 (Two-hybrid), PNMA1 (Two-hybrid), CEP72 (Two-hybrid), FATE1 (Two-hybrid), FAM9B (Two-hybrid), ZBTB9 (Two-hybrid), PIN4 (Affinity Capture-RNA), CCT5 (Co-fractionation), DYNC1H1 (Co-fractionation), MARS (Co-fractionation), PIN4 (Co-fractionation), PIN4 (Co-fractionation), PIN4 (Co-fractionation), CHST15 (Affinity Capture-MS), FRMD1 (Two-hybrid)

ESM2 similar proteins: A0JNJ5, A6QPY8, B5KFL3, F1Q749, F1RRT2, F8RP11, O43100, O43102, O60832, O88600, P02600, P02606, P05977, P08590, P09541, P09542, P12829, P16409, P17209, P34932, P85100, Q12906, Q15147, Q28BT8, Q2TFN9, Q4I665, Q4WJM6, Q503Y7, Q5B5W1, Q5R495, Q5R887, Q5RDM4, Q5ZJH9, Q5ZLF0, Q5ZLN5, Q61316, Q66T82, Q6GL57, Q6P4K8, Q6P848

Diamond homologs: A1VYV6, A4IKU2, A5I7R3, A5N4J2, A6QI23, A6QPY8, A6U2U4, A7FPK5, A7GJD2, A7X3U8, A8YY10, B1IGZ5, B1KTE0, B1YK87, B5KFL3, B9DY54, C1FNE4, C3KW94, C5D6L9, O74448, P0ABZ6, P0ABZ7, P0ABZ8, P0ABZ9, P0C2B5, P0DMT5, P24327, P40415, P44092, P56112, P60747, P60748, P60749, P60750, Q02473, Q02VE3, Q03GD4, Q03QE1, Q07YK0, Q0HLT0

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
CSNK2A1	“down-regulates activity”	PIN4	phosphorylation
PIN4	up-regulates	“Ribosome biogenesis”
PIN4	up-regulates	rRNA_transcription
PIN4	“up-regulates activity”	IRS1	isomerization

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 31 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
RAF/MAP kinase cascade	5	13.3×	6e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

42 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	19
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1750 predictions. Top by Δscore:

Variant	Effect	Δscore
X:72186457:AAAG:A	acceptor_gain	1.0000
X:72186457:AAAGG:A	acceptor_gain	1.0000
X:72186531:AAAG:A	donor_loss	1.0000
X:72186535:G:A	donor_loss	1.0000
X:72186536:T:A	donor_loss	1.0000
X:72195195:GA:G	donor_gain	1.0000
X:72196780:TGCA:T	acceptor_loss	1.0000
X:72196781:GCAG:G	acceptor_loss	1.0000
X:72196783:A:AG	acceptor_gain	1.0000
X:72196784:G:GG	acceptor_gain	1.0000
X:72196784:GGTC:G	acceptor_gain	1.0000
X:72196784:GGTCA:G	acceptor_gain	1.0000
X:72196902:GGG:G	donor_gain	1.0000
X:72196903:GG:G	donor_gain	1.0000
X:72196903:GGG:G	donor_gain	1.0000
X:72196904:GG:G	donor_gain	1.0000
X:72196904:GGT:G	donor_loss	1.0000
X:72196905:G:T	donor_loss	1.0000
X:72196906:T:TC	donor_loss	1.0000
X:72238841:TACCT:T	donor_loss	1.0000
X:72272768:TTGCC:T	acceptor_gain	1.0000
X:72272769:TGCC:T	acceptor_gain	1.0000
X:72272770:GCC:G	acceptor_gain	1.0000
X:72272771:CC:C	acceptor_gain	1.0000
X:72272771:CCC:C	acceptor_gain	1.0000
X:72272772:CC:C	acceptor_gain	1.0000
X:72272773:C:CC	acceptor_gain	1.0000
X:72272773:C:T	acceptor_gain	1.0000
X:72272774:T:A	acceptor_loss	1.0000
X:72273228:TTACC:T	donor_loss	1.0000

AlphaMissense

870 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:72196795:T:A	I43N	1.000
X:72196801:G:A	C45Y	1.000
X:72196802:T:G	C45W	1.000
X:72197423:C:A	A98E	1.000
X:72197477:T:A	V116D	1.000
X:72197483:C:T	T118I	1.000
X:72197488:T:C	F120L	1.000
X:72197490:T:A	F120L	1.000
X:72197490:T:G	F120L	1.000
X:72197491:G:A	G121R	1.000
X:72197491:G:C	G121R	1.000
X:72197492:G:A	G121E	1.000
X:72197492:G:T	G121V	1.000
X:72197504:T:A	I125N	1.000
X:72196786:T:A	V40D	0.999
X:72196789:G:C	R41T	0.999
X:72196789:G:T	R41I	0.999
X:72196791:C:A	H42N	0.999
X:72196791:C:G	H42D	0.999
X:72196792:A:G	H42R	0.999
X:72196793:C:A	H42Q	0.999
X:72196793:C:G	H42Q	0.999
X:72196795:T:C	I43T	0.999
X:72196795:T:G	I43S	0.999
X:72196798:T:C	L44P	0.999
X:72196800:T:C	C45R	0.999
X:72196827:G:C	A54P	0.999
X:72196828:C:A	A54D	0.999
X:72196840:T:C	L58S	0.999
X:72196857:T:C	F64L	0.999

dbSNP variants (sampled 300 via entrez): RS1000086952 (X:72190739 G>A), RS1000098291 (X:72186776 C>T), RS1000307391 (X:72231737 A>G), RS1000381258 (X:72222482 C>T), RS1000526361 (X:72252008 C>T), RS1000603897 (X:72199285 A>C), RS1000648071 (X:72215339 A>G), RS1000698302 (X:72238274 C>T), RS1000732667 (X:72226010 T>C), RS1000749566 (X:72212739 G>A,T), RS1000835180 (X:72186466 G>T), RS1000901144 (X:72188718 C>G), RS1000902268 (X:72261095 C>T), RS1000957922 (X:72216201 C>G,T), RS1000976185 (X:72213325 C>G)

Disease associations

OMIM: gene MIM:300252 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST005790_47	Rosacea symptom severity	7.000000e-06
GCST012466_5	Autism spectrum disorder	6.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0009180	rosacea severity measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4923 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

1 potent at pChembl≥5 of 4 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.82	IC50	1500	nM	CHEMBL2409076

PubChem BioAssay actives

1 with measured affinity, of 8 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
ethyl 2-[13-(2-ethoxy-2-oxoethyl)-5,7,12,14-tetraoxo-6,13-diazatetracyclo[6.6.2.04,16.011,15]hexadeca-1(15),2,4(16),8,10-pentaen-6-yl]acetate	761671: Inhibition of Par14 (unknown origin)	ic50	1.5000	uM

CTD chemical–gene interactions

38 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	3
bisphenol A	affects cotreatment, decreases methylation, increases expression	2
sodium arsenite	affects methylation, affects cotreatment, increases expression	2
Benzo(a)pyrene	affects methylation, decreases expression, increases methylation	2
Cyclosporine	decreases expression	2
Aflatoxin B1	decreases methylation, increases methylation	2
bisphenol F	increases expression	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
terbufos	increases methylation	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
potassium chromate(VI)	decreases expression	1
nutlin 3	affects cotreatment, increases secretion	1
ICG 001	decreases expression	1
bisphenol B	increases expression	1
abrine	decreases expression	1
bisphenol S	increases expression	1
MT19c compound	increases expression	1
bisphenol AF	increases expression	1
Temozolomide	decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Acetaminophen	decreases expression	1
Arsenic	affects methylation	1
Cannabidiol	decreases expression	1
Dactinomycin	affects cotreatment, increases secretion	1
Fonofos	increases methylation	1
Ivermectin	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Parathion	increases methylation	1
Ribonucleotides	affects binding	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2410563	Binding	Inhibition of Par14 (unknown origin)	Pin1 inhibitors: Pitfalls, progress and cellular pharmacology. — Bioorg Med Chem Lett

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.